Grace Therapeutics, Inc.
GRCE
Rank in Stocks
#24815
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Share Price
$1.87
Last synced: 2026-11-09
Market Cap
$30.35M
Change (1 day)
0.81%
Change (1 year)
-37.83%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Grace Therapeutics, Inc. (GRCE)
Category
Healthcare
Operating Margin for Grace Therapeutics, Inc. (GRCE)
Operating Margin as of November 2026 TTM: 0.00%
According to Grace Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Grace Therapeutics, Inc. from 2010 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -8,377.04% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | -100.00% |
| 2016 | -25,526.33% | 457.29% |
| 2015 | -4,580.47% | 112.44% |
| 2014 | -2,156.13% | 123.71% |
| 2013 | -963.82% | -98.46% |
| 2012 | -62,535.93% | 469.53% |
| 2011 | -10,980.25% | 0.00% |
| 2010 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Grace Therapeutics, Inc.'s operating margin
What was Grace Therapeutics, Inc.'s operating margin in 2025?
In 2025, Grace Therapeutics, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Grace Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Grace Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2021 (-8,377.04%).
How does Grace Therapeutics, Inc.'s operating margin compare with similar companies?
Grace Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.